Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2).

  title={Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2).},
  author={Lewis J. Rubin and Nazzereno Gali{\`e} and Friedrich Grimminger and Ekkehard Gruenig and Marc Humbert and Zhi-Cheng Jing and Anne M. Keogh and David Langleben and Arno Fritsch and Flavia Menezes and Neil Davie and Hossein Ardeschir Ghofrani},
  journal={The European respiratory journal},
  volume={45 5},
Riociguat is a soluble, guanylate cyclase stimulator, approved for pulmonary arterial hypertension. In the 12-week PATENT-1 study, riociguat was well tolerated and improved several clinically relevant end-points in patients with pulmonary arterial hypertension who were treatment naïve or had been pretreated with endothelin-receptor antagonists or prostanoids. The PATENT-2 open-label extension evaluated the long-term safety and efficacy of riociguat. Eligible patients from the PATENT-1 study… CONTINUE READING
Highly Influential
This paper has highly influenced 30 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS


Publications citing this paper.
Showing 1-10 of 295 extracted citations

Riociguat: First Global Approval

View 17 Excerpts
Highly Influenced

Brief Review of Pharmacotherapy for Pulmonary Arterial

Hypertension Chokkalingam, A Scharf
View 3 Excerpts
Highly Influenced

Pulmonary hypertension associated with lung diseases and hypoxemia

Heart Failure Reviews • 2016
View 7 Excerpts
Highly Influenced


Publications referenced by this paper.
Showing 1-10 of 19 references

[Updated treatment algorithm of pulmonary arterial hypertension].

Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir • 2014

Riociguat for the treatment of pulmonary arterial hypertension

HA Ghofrani, N Galiè, F Grimminger
N Engl J Med • 2013

Similar Papers

Loading similar papers…